

BRA-24P、BRA-48P 使用論文

- 1) Kim JL, Osteogenic activity of yellow flag iris (*Iris pseudacorus*) extract modulating differentiation of osteoblasts and osteoclasts. *Am J Chin Med.* 2012, 40(6):1289-305.
- 2) Wu K, Dextromethorphan inhibits osteoclast differentiation by suppressing RANKL-induced nuclear factor- κ B activation. *Osteoporos Int.* 2013, 24(8):2201-14.
- 3) Kanzaki H, The keap1/nrf2 protein axis plays a role in osteoclast differentiation by regulating intracellular reactive oxygen species signaling. *J Biol Chem.* 2013, 288(32):23009-20.
- 4) Moon SJ, Temporal differential effects of proinflammatory cytokines on osteoclastogenesis. *Int J Mol Med.* 2013, 31(4):769-77.
- 5) Fabre C, Dual inhibition of canonical and noncanonical NF- κ B pathways demonstrates significant antitumor activities in multiple myeloma. *Clin Cancer Res.* 2012, 18(17):4669-81.
- 6) Harada K, Polyphosphate-Mediated Inhibition of Tartrate-Resistant Acid Phosphatase and Suppression of Bone Resorption of Osteoclasts. *PLoS One.* 2013, 8(11): e78612
- 7) Hokugo A, Equilibrium-dependent bisphosphonate interaction with crystalline bone mineral explains anti-resorptive pharmacokinetics and prevalence of osteonecrosis of the jaw in rats. *Bone.* 2013, 53:59-68.
- 8) Eda H, A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity. *Leukemia.* 2014, 28(9):1892-901
- 9) Orosa B, Lysophosphatidic acid receptor inhibition as a new multipronged treatment for rheumatoid arthritis. *Ann Rheum Dis.* 2014, 73(1):298-305
- 10) Sharma R, Caspase-2 maintains bone homeostasis by inducing apoptosis of oxidatively-damaged osteoclasts. *PLoS One.* 2014, 9(4):e93696

- 11) Hsieh CJ, Wedelolactone inhibits breast cancer-induced osteoclastogenesis by decreasing Akt/mTOR signaling. *Int J Oncol*, 2015, 46(2):555-62.
- 12) Mishima K, Lansoprazole Upregulates Polyubiquitination of the TNF Receptor-Associated Factor 6 and Facilitates Runx2-mediated Osteoblastogenesis. *EBioMedicine*. 2015, 2(12):2046-61
- 13) Ishikawa S, Inductive Effect of Palmatine on Apoptosis in RAW 264.7 Cells. *Evid Based Complement Alternat Med*. 2016;2016:7262054
- 14) Wijekoon S, Chronological differential effects of pro-inflammatory cytokines on RANKL-induced osteoclast differentiation of canine bone marrow-derived macrophages. *J Vet Med Sci*. 2017, 79(12):2030-2035.
- 15) Kanzaki H, Nuclear Nrf2 induction by protein transduction attenuates osteoclastogenesis. *Free Radic Biol Med*. 2014, 77:239-48.
- 16) Maruyama K, Nociceptors Boost the Resolution of Fungal Osteoinflammation via the TRP Channel-CGRP-Jdp2 Axis. *Cell Rep*, 2017, 19(13):2730-2742.
- 17) Wijekoon HMS, Inhibitory effects of sodium pentosan polysulfate on formation and function of osteoclasts derived from canine bone marrow. *BMC Vet Res*. 2018, 14(1):152.
- 18) Jin SH, Actin-binding LIM Protein 1 Regulates Receptor Activator of NF- κ B Ligand-Mediated Osteoclast Differentiation and Motility. *BMB Rep*. 2018 Jul;51(7):356-361.
- 19) Nishida M, S100A12 facilitates osteoclast differentiation from human monocytes. *PLoS One*. 2018, 13(9):e0204140.
- 20) Ohnuma K, MicroRNA-124 inhibits TNF- α and IL-6-induced osteoclastogenesis. *Rheumatol Int*. 2019, 39(4):689-695.
- 21) Kumagai M, Fluorinated Kavalactone Inhibited RANKL-Induced Osteoclast Differentiation of RAW264 Cells. *Biol Pharm Bull*. 2020, 43(5):898-903.

- 22) Lee EJ, Coumarin Ameliorates Impaired Bone Turnover by Inhibiting the Formation of Advanced Glycation End Products in Diabetic Osteoblasts and Osteoclasts. *Biomolecules*, 2020, 10(7):1052.
- 23) Nishioku T, (-)-Epigallocatechin-3-gallate inhibits RANKL-induced osteoclastogenesis via downregulation of NFATc1 and suppression of HO-1-HMGB1-RAGE pathway. *Biomed Res.* 2020, 41(6):269-277.
- 24) Park KH, Inhibitory Effect of *Rosae Multiflorae Fructus* Extracts on the Receptor Activator of NF- κ B Ligand-Induced Osteoclastogenesis through Modulation of P38- and Ca²⁺-Mediated Nuclear Factor of Activated T-Cells Cytoplasmic 1 Expression. *J Bone Metab.* 2020, 27(1):53-63.
- 25) Wada S, Bach1 Inhibition Suppresses Osteoclastogenesis via Reduction of the Signaling via Reactive Oxygen Species by Reinforced Antioxidation. *Front Cell Dev Biol*, 2020, 8:740.
- 26) Jeong S, Isoliquiritigenin Derivatives Inhibit RANKL-Induced Osteoclastogenesis by Regulating p38 and NF- κ B Activation in RAW 264.7 Cells. *Molecules*, 2020, 25(17):3908.
- 27) Lee EJ, Hydroxycoumarin Scopoletin Inhibits Bone Loss through Enhancing Induction of Bone Turnover Markers in a Mouse Model of Type 2 Diabetes. *Biomedicines*, 2021, 9(6):648.
- 28) Zhen G, An antibody against Siglec-15 promotes bone formation and fracture healing by increasing TRAP⁺ mononuclear cells and PDGF-BB secretion. *Bone Res*, 2021, 9(1):47.
- 29) Cho E, Identification of Novel Genes for Cell Fusion during Osteoclast Formation. *Int J Mol Sci*, 2022, 23(12):6421.
- 30) Kelk P, *Aggregatibacter actinomycetemcomitans* Leukotoxin Activates the NLRP3 Inflammasome and Cell-to-Cell Communication. *Pathogens*, 2022,11(2):159.

- 31) Wijekoon S, Pentosan polysulfate regulates hepcidin 1-facilitated formation and function of osteoclast derived from canine bone marrow. *PLoS One*, 2022, 17(3):e0265596.
- 32) Okawa H, Mechanism of bisphosphonate-related osteonecrosis of the jaw (BRONJ) revealed by targeted removal of legacy bisphosphonate from jawbone using competing inert hydroxymethylene diphosphonate. *eLife*. 2022; 11: e76207.
- 33) Chen Qi, Aberrant activation of TGF- β 1 induces high bone turnover via Rho GTPases-mediated cytoskeletal remodeling in Camurati-Engelmann disease. *Front Endocrinol (Lausanne)*. 2022; 13: 913979.
- 34) Kang IH, Quantitative increase in T regulatory cells enhances bone remodeling in osteogenesis imperfecta. *iScience*. 2022, 25(9):104818.